Supernus Pharmaceuticals Inc (SUPN)
EBITDA Margin
-1.91%
TTM · Period ending:
SUPN EBITDA Margin
Latest reported-1.91%period ending
Latest reported-1.91%period ending
SUPN TTM EBITDA Margin (383.22% → -1.91%)
TTM ebitda margin
High-resolution chart · PNG
SUPN ebitda margin history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Margin |
|---|---|
| -1.9108% | |
| 6.661% | |
| 6.8625% | |
| 9.9617% | |
| 24.9706% | |
| 24.9988% | |
| 25.0379% | |
| 21.9555% | |
| 17.4312% | |
| 12.6249% | |
| 14.8214% | |
| 20.4673% | |
| 18.3387% | |
| 21.9077% | |
| 22.9837% | |
| 17.6741% | |
| 21.4214% | |
| 23.88% | |
| 22.2833% | |
| 28.3209% | |
| 32.3831% | |
| 35.5242% | |
| 40.4582% | |
| 43.5056% | |
| 44.2927% | |
| 45.229% | |
| 45.1182% | |
| 45.1542% | |
| 43.2101% | |
| 40.6479% | |
| 40.4765% | |
| 38.2734% | |
| 37.1614% | |
| 36.7796% | |
| 35.6252% | |
| 32.0903% | |
| 32.6047% | |
| 29.6147% | |
| 26.6203% | |
| 24.7713% | |
| 18.6875% | |
| 15.2992% | |
| 15.0693% | |
| 14.3062% | |
| 8.9886% | |
| 9.2801% | |
| -4.3123% | |
| -21.418% | |
| -83.9911% | |
| -340.4047% | |
| -623.6958% | |
| -2,751.0991% | |
| -4,201.8024% | |
| -3,624.3129% | |
| -2,808.1757% | |
| 516.6896% | |
| 485.097% | |
| 513.2943% | |
| 515.5108% | |
| 586.5289% | |
| 383.2152% |